Enveda, a clinical-stage drug developer, raised a $150 million Series D at a valuation north of $1 billion, CEO Viswa Colluru tells Axios Pro. Why it matters: The company has raised $350 million in ...

The Neetcode 150 is a curated set of coding problems covering the most common interview topics and patterns. It stands out ...